Aequo has successfully defended the rights of Ukraine's Darnitsa pharmaceutical company to the shares of the Borshchahivskiy chemical-pharmaceutical plant in the Supreme Court of Ukraine.
Darnitsa acquired 3,100 shares (29.95% of the charter capital) of the SIC Borshchahivskiy chemical-pharmaceutical plant from the Department of Kyiv Communal Property at a privatization auction on March 20, 2015.
According to Aequo, “on October 29, 2020, the Supreme Court granted the cassation appeal of Darnitsa and canceled the groundless resolution of the Northern Commercial Court of Appeal from August 25, 2020, concerning [the] acquisition of shares of the SIC Borshchahivskiy chemical-pharmaceutical plant by Darnitsa ... and ultimately confirmed [the company's] right to the shares.“
The Supreme Court’s decision is final and not subject to further appeal. “Earlier,” Aequo report, “the Supreme Court also confirmed the validity of the decision of the Antimonopoly Committee of Ukraine on granting Darnitsa merger clearance for its acquisition of the above-mentioned shares.”
Aequo’s team included Counsel Yevgen Levitskyi and Associate Oleksandr Zubrytskyi.